CHICAGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the presentation of interim data from an ongoing phase I clinical trial of SGN-75 in renal cell carcinoma (RCC) and non-Hodgkin lymphoma at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting being held in Chicago, IL. SGN-75 is an antibody-drug conjugate (ADC) targeted to CD70. The interim data suggest that SGN-75 is generally well tolerated and induces objective responses in heavily pretreated RCC and non-Hodgkin lymphoma patients.
